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Abstract
Background: Snake bite is a common medical emergency in Papua New Guinea (PNG). The taipan, Oxyuranus scutellatus,
inflicts a large number of bites that, in the absence of antivenom therapy, result in high mortality. Parenteral administration
of antivenoms manufactured in Australia is the current treatment of choice for these envenomings. However, the price of
these products is high and has increased over the last 25 years; consequently the country can no longer afford all the
antivenom it needs. This situation prompted an international collaborative project aimed at generating a new, low-cost
antivenom against O. scutellatus for PNG.
Methodology/Principal Findings: A new monospecific equine whole IgG antivenom, obtained by caprylic acid fractionation
of plasma, was prepared by immunising horses with the venom of O. scutellatus from PNG. This antivenom was compared
with the currently used F(ab’)2 monospecific taipan antivenom manufactured by CSL Limited, Australia. The comparison
included physicochemical properties and the preclinical assessment of the neutralisation of lethal neurotoxicity and the
myotoxic, coagulant and phospholipase A2 activities of the venom of O. scutellatus from PNG. The F(ab’)2 antivenom had a
higher protein concentration than whole IgG antivenom. Both antivenoms effectively neutralised, and had similar potency,
against the lethal neurotoxic effect (both by intraperitoneal and intravenous routes of injection), myotoxicity, and
phospholipase A2 activity of O. scutellatus venom. However, the whole IgG antivenom showed a higher potency than the
F(ab’)2 antivenom in the neutralisation of the coagulant activity of O. scutellatus venom from PNG.
Conclusions/Significance: The new whole IgG taipan antivenom described in this study compares favourably with the
currently used F(ab’)2 antivenom, both in terms of physicochemical characteristics and neutralising potency. Therefore, it
should be considered as a promising low-cost candidate for the treatment of envenomings by O. scutellatus in PNG, and is
ready to be tested in clinical trials.
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Introduction
Envenoming by snake bite is a common medical emergency in
Papua New Guinea (PNG) [1–3]. Despite incomplete epidemio-
logical data, studies in PNG show that the incidence of snake bite
ranges from under five cases per 100,000 people per year in the
mountains of Goilala and Hiri (Central Province) and in Madang,
to 526–561 cases per 100,000 people per year in the coastal
Kairuku lowlands [1,2,4]. A mortality rate of 7.9 deaths per
100,000 people per year in Central Province was reported for the
period 1987–1992 [2]. At Port Moresby General Hospital
(PMGH) only envenomed snakebite patients are admitted, and
most of these are sent to the Intensive Care Unit (ICU). A study of
snakebite admissions to the PMGH ICU between 1992 and 2001
revealed case fatality rates of 8.2% for adults and 14.6% for
children [5]. More recently, case fatality rates of 14.5% for adults
and 25.9% for children have been reported from the ICU of the
same hospital [3].
Throughout PNG three species of elapid snakes are responsible
for nearly all systemic envenomings: Acanthophis laevis (smooth-
scaled death adder), Micropechis ikaheka (New Guinea small-eyed
snake), and Oxyuranus scutellatus (Papuan taipan). A very small
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number of envenomings are caused by other Acanthophis species,
Pseudechis papuanus (Papuan blacksnake) and Pseudonaja textilis (New
Guinea brownsnake) [3]. For many years the Papuan taipan has
been regarded as a separate subspecies (Oxyuranus s. canni) to
Australian populations (Oxyuranus s. scutellatus). However, recent
taxonomic and biogeographical studies have shown that, despite
some perceived morphological differences, molecular genetic
analysis reveals no significant differentiation between the two
populations [6,7]. On this basis, O. scutellatus is now considered a
single species with both Australian and New Guinean populations.
In southern PNG and neighbouring southern Papua, up to 95% of
life-threatening snake bites are caused by O. scutellatus (Fig 1). The
effects of taipan bite include mild local effects and severe systemic
manifestations characterised by coagulopathy with spontaneous
systemic haemorrhage, myotoxicity, irreversible flaccid paralysis,
acute kidney injury and cardiac disturbances [2,3,8–10]. The
neurotoxic manifestations of taipan bite are dominated by the
effects of extremely potent, destructive, presynaptic phospholipase
A2 toxins, resulting in physical damage to nerve terminals [11,12].
Only the early (within 4–6 hours) administration of suitable
antivenom can prevent or reduce this presynaptic damage;
consequently, when treatment is delayed, severe paralysis occurs,
requiring endotracheal intubation and mechanical ventilation until
neuromuscular synapses have regenerated [2,13].
Intravenous administration of either taipan monospecific
antivenom or polyvalent antivenom prepared in Australia by
CSL Limited (CSL) against the venom of Australian O. scutellatus,
has been the only effective treatment for envenomings by O.
scutellatus in PNG [2,3,14]. In vitro preincubation studies, using
chick biventer cervicis preparations, have shown that this
antivenom inhibits the neurotoxic effects of O. scutellatus venom
sourced in Indonesian Papua [15], and clinical observations in
PNG have shown its effectiveness in halting spontaneous systemic
bleeding and restoring blood coagulability [2,14]. Administration
of antivenom within four hours of envenoming significantly
reduces the incidence of respiratory paralysis [2]. Therefore, a
critical issue concerning the management of O. scutellatus
envenoming in PNG is the need for rapid access to antivenom,
which in turn demands its widespread distribution to hospitals and
other health centres. One critical factor limiting the availability of
CSL antivenom in PNG is its high price, which has increased
more than 800% over the last two decades [5,16], greatly reducing
the capacity of the health system to purchase adequate volumes to
meet all of the country’s needs, leading to chronic shortages. As a
consequence, a thriving black market in stolen antivenoms has
developed, with private sellers charging as much as US$3,200.00/
vial [17].
An alternative method for manufacturing antivenoms is based
on the purification of horse IgG antibodies by fractionation of
hyperimmune plasma with caprylic acid [18–21]. This simple and
inexpensive procedure yields a highly purified whole IgG
preparation [19]. Polyspecific antivenoms prepared in this way,
at relatively low cost, have been tested in clinical trials in Colombia
[22–24] and Nigeria [25], and displayed excellent efficacy and
safety. We describe a collaborative effort between teams in Costa
Rica, Australia and PNG in the preparation and preclinical
evaluation of a monospecific whole IgG antivenom against the
venom of O. scutellatus from PNG, and have compared it with the
Australian-made CSL taipan antivenom currently in use.
Methods
Venom
A pool of two grams of venom was obtained from twelve
healthy, adult specimens of O. scutellatus collected in PNG’s Milne
Bay Province and Central Province. These snakes were main-
tained in a purpose-built serpentarium at the University of PNG,
and venom was collected at 21 day intervals. Venom was obtained
using Parafilm-covered 50 mL Eppendorf tubes. Samples con-
taminated by blood were discarded, and all samples were handled
using plastic pipettes and tubes. Venom was snap-frozen to
280uC, before being freeze-dried and stored away from light at
220uC. In some experiments, the venom of Australian O. scutellatus
obtained from Venom Supplies Pty Limited (Tanunda, South
Australia) was used for comparative purposes. In all experiments,
lyophilized venom was dissolved in 0.14 M NaCl, 0.04 M
phosphate, pH 7.2 (PBS) immediately before use.
Antivenoms
Two antivenoms were used in this study:
N (a). Monospecific taipan antivenom manufactured by CSL
Limited (CSL), Melbourne, Victoria, Australia (batch B0548-
06301; expiry date March 2012).
N (b). Monospecific taipan antivenom manufactured by Instituto
Clodomiro Picado (ICP) (batch 4511209 ICP; expiry date
November 2012).
Antivenom Production
CSL monospecific taipan antivenom is prepared from the
plasma of horses immunised with the venom of O. scutellatus from
Australia. It is manufactured using a protocol based on pepsin
digestion and ammonium sulphate fractionation of plasma, and
therefore consists of F(ab’)2 fragments [26]. ICP monospecific
taipan antivenom is raised in horses immunised with the venom of
O. scutellatus from PNG. Immunisation was performed in a group
of three horses which had not previously been used for antibody
production, by using Freund’s complete and incomplete adjuvants
during the first two injections, respectively, followed by subsequent
inoculations of venom dissolved in PBS. All injections were
performed by the subcutaneous route in a single anatomical site.
Author Summary
Snake bite envenoming represents an important public
health hazard in Papua New Guinea (PNG). In the southern
lowlands of the country the majority of envenomings are
inflicted by the taipan, Oxyuranus scutellatus. The only
currently effective treatment for these envenomings is the
administration of antivenoms manufactured in Australia.
However, the price of these products in PNG is very high
and has steadily increased over the last 25 years, leading to
chronic antivenom shortages in this country. As a response
to this situation, an international partnership between
PNG, Australia and Costa Rica was initiated, with the aim of
generating a new, low-cost antivenom for the treatment of
PNG taipan envenoming. Horses were immunised with the
venom of O. scutellatus from PNG and whole IgG was
purified from the plasma of these animals by caprylic acid
precipitation of non-immunoglobulin proteins. The new
antivenom, manufactured by Instituto Clodomiro Picado
(Costa Rica), was compared with the currently available
F(ab’)2 antivenom manufactured by CSL Limited (Australia).
Both were effective in the neutralisation of the most
relevant toxic effects induced by this venom, although the
whole IgG antivenom showed a higher efficacy than the
F(ab’)2 antivenom in the neutralisation of the coagulant
activity.
Papuan Taipan Antivenom
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When a satisfactory neutralising titre was reached, the animals
were bled from the jugular vein, with the blood being collected in
6 L plastic bags containing sodium citrate as anticoagulant. After
sedimentation of blood cells, the plasma was separated and the
immunoglobulins purified by caprylic acid precipitation (5% final
concentration of caprylic acid and one hr stirring) [19]. After
filtration in 8 mm pore filter paper, the filtrate was diafiltered and
then formulated to contain 7.5 g/L NaCl, 1.6 g/L phenol, pH 7.2
Figure 1. Oxyuranus scutellatus from Papua New Guinea. Adult specimen from Padi Padi, Milne Bay Province, Papua New Guinea, and
distribution map showing the range of this species in PNG and Indonesia’s Papua Province (Photo and artwork: DJ Williams).
doi:10.1371/journal.pntd.0001144.g001
Papuan Taipan Antivenom
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(Table 1). The antivenom solution was sterile filtered using
0.22 mm pore membranes and glass vials were filled with 40 mL of
antivenom. The resultant antivenom met all the requirements of
the quality control protocol at Instituto Clodomiro Picado.
Physicochemical analysis of antivenoms
Total protein concentration was determined by the Biuret test
[27], and electrophoretic analysis was performed by SDS-PAGE,
under non-reducing conditions, using an acrylamide concentration
of 7.5% [28]. Gels were stained with Coomassie Brilliant Blue R-
250. Phenol concentration was determined according to a
modification of the method of Lacoste et al. [29]. Caprylic acid
concentration was quantified by HPLC according to Herrera et al.
[30]. The content of antibody monomers was assessed by FPLC
gel filtration in a Superdex 200 10/300 GL column using 0.15 M
NaCl, 20 mM Tris, pH 7.5, as eluent. Turbidity was determined
using a turbidimeter (La Motte, model 2020, Chestertown, MD),
and expressed as nephelometric turbidity units (NTU).
Toxic and enzymatic activities of venoms and
neutralisation by antivenoms
Ethics statement. The experimental protocols involving the
use of animals in this study were approved by the Institutional
Committee for the Care and Use of Laboratory Animals (CICUA)
of the University of Costa Rica, and adhere to the International
Guiding Principles for Biomedical Research Involving Animals of
the Council of International Organizations of Medical Sciences
(CIOMS).
Lethal activity. Groups of 5 CD-1 mice of both sexes were
injected via either the intraperitoneal (i.p.; 16–18 g mice) or the
intravenous (i.v.; 18–20 g mice) routes with various amounts of PNG
O. scutellatus venom, dissolved in PBS. The volume of injection was
0.5 mL when using the i.p. route and 0.2 mL when using the i.v.
route. Deaths occurring during 48 hr were recorded and the Median
Lethal Dose (LD50) was estimated by Spearman-Karber [31].
Myotoxic activity. Groups of 4 CD-1 mice (18–20 g) of both
sexes were injected intramuscularly (i.m.), in the right gastroc-
nemius, with various amounts of venom dissolved in 50 mL PBS.
Control mice received 50 mL PBS under otherwise identical
conditions. After three hr, mice were bled from the tail and the
blood was collected into heparinised capillary tubes. After
centrifugation, plasma was collected and the creatine kinase
(CK) activity of plasma was quantified by using a commercial kit
(CK-Nac, Biokon Diagnostik, Germany). The Minimum Myotoxic
Dose (MMD) corresponds to the dose of venom that induced an
increment in plasma CK activity corresponding to four times the
CK activity of mice injected with PBS [32].
Coagulant activity. The method described by Theakston
and Reid [33] and Gene´ et al. [34] was followed. Various amounts
of venom, dissolved in 100 mL of 0.15 M NaCl, were added to
aliquots of 200 mL of human citrated plasma previously incubated
at 37uC for 5 min. Experiments were run in quadruplicate.
Clotting times were recorded, and the Minimum Coagulant
Concentration (MCC) was determined. The MCC corresponds to
the concentration of venom that induced plasma clotting in 60 sec.
Experiments were performed in both citrated plasma and in
citrated plasma to which CaCl2 was added (15 mL of 0.2 M CaCl2
to 200 mL plasma) immediately before addition of the venom, as
previously described [35,36].
Phospholipase A2 (PLA2) activity. PLA2 activity was
determined titrimetrically, using egg yolk phospholipids as
substrates, as previously described [37]. Activity was expressed
as mEq fatty acid released per mg protein per min.
Neutralisation of venom activities by antivenoms. A fixed
venom dose (‘‘challenge dose’’) was pre-incubated with various
dilutions of antivenom prior to testing in the corresponding
experimental systems, as previously described [32,38]. The
following challenge doses of venom were used: Lethality (four
venom LD50s); coagulant effect (two venom MCCs); myotoxicity
(one venom MMD since higher doses were lethal); PLA2 activity
(1.5 mg venom). For each effect, the challenge dose of venom was
incubated with various dilutions of antivenom, in order to achieve
several ratios of mg venom/mL antivenom. Controls included
venom incubated with PBS, or 0.15 M NaCl in the case of
coagulant effect, instead of antivenom. Incubations were performed
for 30 min at 37uC and then aliquots of the mixtures, containing the
challenge dose of venom, were tested in the relevant assay systems
described above. In the case of coagulant effect, mixtures of venom
and antivenom used in the coagulation assay were incubated for no
more than 3 min at room temperature (22–25uC) before testing,
because incubation of venom for 30 min resulted in a partial loss of
coagulant activity (see below). The neutralising ability of antivenoms
for lethal and PLA2 activities were expressed as Median Effective
Dose (ED50), corresponding to the ratio mg venom/mL antivenom
in which the activity of the venom was reduced by 50% [38]. In the
case of the coagulant effect, neutralisation was expressed as Effective
Dose (ED), corresponding to the ratio mg venom/mL antivenom in
which the clotting time is prolonged three times as compared with
the clotting time of plasma incubated with venom alone [34]. On
the other hand, the estimation of the neutralizing potency against
myotoxicity could not follow the method previously described [32],
since the challenge dose used (1 mg) induced a relatively small
increment in plasma CK, and higher doses were lethal. Thus, the
increment in plasma CK activity in control mice injected with 1 mg
of venom alone was only 4 times the value of CK in mice injected
with PBS. In these conditions, the value of ED was defined as the
ratio mg venom/mL antivenom in which the plasma CK activity
was not significantly different from the plasma CK activity of mice
injected with PBS alone, i.e. where myotoxicity was completely
abrogated.
Variation of venom activities upon incubation
Pre-incubation of PNG O. scutellatus venom at 37uC for 30 min
resulted in a significant loss of coagulant activity. Thus, it was
considered that degradation of the procoagulant toxins may be
occurring. On this basis, all of the venom activities assessed in this
study (LD50, MCC, MMD and PLA2) were determined for venom
solutions (a) immediately after dissolution in PBS and (b) after
30 min of incubation at 37uC. Lethality (LD50) by both i.p. and i.v.
Table 1. Physicochemical characteristics of antivenoms.
Characteristic ICP IgG antivenom CSL F(ab’)2 antivenom
Protein (g/L) 45.960.9 144.660.4
Phenol (g/L) 1.660.04 2.1260.03
pH 7.2 6.4
Caprylic acid (mg/L) 3161 2
Monomer content (%)a 9361.0 9360.4
Turbidity (NTU)b 25 23
aMonomer content is expressed as the percentage of antivenom protein
present as either IgG or F(ab’)2 monomers, as analyzed by gel filtration (see
Materials and Methods).
bTurbidity is expressed as Nephelometric Turbidity Units (see details in Materials
and Methods).
doi:10.1371/journal.pntd.0001144.t001
Papuan Taipan Antivenom
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routes, myotoxicity (MMD) and PLA2 activity were not affected by
incubation at 37uC for 30 min. In contrast, the coagulant activity
of O. scutellatus venom was reduced upon incubation at 37uC for
30 min. We therefore altered the experimental design of the ED-
MCC assay by limiting incubation of venom and antivenom to not
more than 3 minutes, in order to avoid the loss of activity
associated with incubation.
Statistical analysis
All descriptive statistic calculations and the Mann Whitney U
test used to determine the significance of the differences between
the median values of two non-parametric experimental groups in
the neutralisation tests were performed using the InStat statistics
program.
Results
Characteristics of antivenoms
The physicochemical characteristics of the two antivenoms are
summarised in Table 1. The CSL F(ab’)2 antivenom had a 3.15
fold higher total protein concentration than ICP whole IgG
antivenom. When examined using SDS-PAGE run under non-
reducing conditions, the CSL antivenom, manufactured by pepsin
digestion and ammonium sulphate fractionation, presented
predominant bands in a molecular mass range corresponding to
F(ab’)2 fragments (Fig 2). In contrast, the whole IgG antivenom
fractionated with caprylic acid showed one predominant band of a
molecular mass corresponding to IgG monomers. Both antive-
noms presented additional minor bands of high molecular mass (in
the case of F(ab’)2 antivenom) and of 54 and 58 kDa (in the case of
IgG antivenom) (Fig 2). Both antivenoms were composed by
.90% IgG or F(ab’)2 monomers, as judged by gel filtration
analysis (Table 1; Fig 3), thus showing a very low protein aggregate
content, and had very low turbidity, as assessed both visually and
through quantification by nephelometry (Table 1).
Toxic and enzymatic activities of venom and neutralising
profile of antivenoms
Toxic and enzymatic activities of O. scutellatus
venom. The venom of O. scutellatus is highly toxic for CD-1
mice, with LD50 values of 0.0460.01 mg/mouse (2.360.6 mg/kg)
and 0.0860.01 mg/mouse (4.260.5 mg/kg) for the i.p. and the i.v.
routes, respectively. Lethality was associated with neurotoxicity, as
mice showed evidence of limb and respiratory paralysis. Venom
also caused myotoxicity in mice, with a MMD of 1 mg per mouse,
corresponding to the dose that increased 4 times the plasma CK
activity as compared with mice injected with PBS, which had a
CK activity of 187634 U/L. Mice receiving doses higher than
1 mg died before 3 hr. O. scutellatus venom induced coagulation of
human plasma, with higher activity in conditions in which CaCl2
was added to citrated plasma before the addition of the venom, as
previously reported [35,36]. Without addition of calcium, the
MCC was 0.7660.20 mg/mL, whereas when CaCl2 was added
to plasma immediately before the venom, the MCC was
0.3360.13 mg/mL (p,0.05). The PLA2 activity of this venom
corresponds to 29767 mEq fatty acid released per mg protein per
min (Table 2).
Neutralisation by antivenoms. The two antivenoms were
effective at neutralising the four activities tested. No significant
differences were observed in the ED50 of either product against the
lethal and PLA2 activities of PNG O. scutellatus venom as well as in
the ED against myotoxic effect (Table 2). In contrast with lethal,
PLA2 and myotoxic activities, there was a significant difference in
the value of ED against in vitro coagulant activity of the venom of
O. scutellatus from PNG, with the ICP antivenom having 5.2 times
and 2.9 times the potency of the CSL antivenom, in experiments
performed with calcium and without calcium, respectively
(Table 2). In order to ascertain whether this difference is due to
antigenic variations between the procoagulants of the venoms
from the Australian and Papuan populations of O. scutellatus, the
neutralisation of coagulant activity of the venom of Australian O.
scutellatus, which is used in the immunizing mixture of the CSL
antivenom, was investigated. The MCC of this venom was
1.360.6 mg/mL (in experiments where calcium was added to
Figure 2. Electrophoretic analysis of antivenoms. Non-reduced
samples were loaded in a 7.5% polyacrylamide gel in the presence of
SDS. After separation, proteins were stained with Coomassie Brilliant
Blue R-250. Migration of molecular mass markers is depicted to the left.
doi:10.1371/journal.pntd.0001144.g002
Figure 3. Analysis of antivenoms by gel filtration. Aliquots of the
antivenoms were separated by gel filtration in Superdex 200 10/300 GL
column and elution was carried out with 150 mM NaCl, 20 mM Tris-HCl,
pH 7.5 buffer. Both antivenoms showed a major peak, corresponding to
either F(ab’)2 or IgG monomers, which comprise .90% of the total
protein.
doi:10.1371/journal.pntd.0001144.g003
Papuan Taipan Antivenom
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plasma) and 4.160.6 mg/mL (without added calcium) (p,0.05).
Both antivenoms effectively neutralized this activity, with ICP
antivenom showing a higher potency. The EDs in conditions
where calcium was added were 10.062.5 mg venom neutralized
per mL (ICP antivenom) and 4.161.4 mg venom/mL antivenom
(CSL antivenom) (p,0.05). On the other hand, when calcium was
not added to plasma, the values of EDs were 4.960.4 mg venom/
mL antivenom (ICP antivenom) and 1.560.2 mg venom/mL
antivenom (CSL antivenom) (p,0.05). When comparing the
neutralizing ability of the antivenoms against all effects studied,
since the CSL antivenom contains 3.15 times the protein of the
ICP antivenom, a lesser amount of antivenom protein is required
to achieve neutralisation of the various effects in the case of ICP
antivenom.
Discussion
In the present work, a new, whole IgG monospecific antivenom,
obtained by caprylic acid precipitation, was prepared against the
venom of Papua New Guinean O. scutellatus, the most medically
important venomous snake in the southern halves of both PNG
and Indonesian Papua. It was shown that, in standard WHO-
endorsed preclinical neutralisation assays, against venom of O.
scutellatus from PNG, this new antivenom compares very
favourably with the F(ab’)2 taipan antivenom currently in use in
Australia and PNG.
The venoms of Oxyuranus spp. are among the most toxic ever
reported [39], and our LD50 data on mice confirm the high
toxicity of O. scutellatus from PNG. This high toxicity is due
predominantly to the presence of a number of neurotoxins, in
particular the presynaptic PLA2 trimer, taipoxin (‘‘cannitoxin’’)
which destroys nerve terminals and also binds to skeletal muscle,
leading to myolysis [11,40–42]. A number of monomeric
neurotoxic and myotoxic PLA2, a 52 kDa multimeric voltage-
dependent calcium channel blocker, taicatoxin, and a 6.7 kDa
post-synaptic a-neurotoxin of 6.7 kDa, a-oxytoxin 1, have also
been characterized [43–47]. The dominance of destructive
presynaptic neurotoxicity in the clinical syndrome of O. scutellatus
envenoming has important implications for the treatment of taipan
bites, since anticholinesterases do not improve neurotransmission,
and more importantly antivenom cannot reverse established
neurotoxic manifestations secondary to physical damage to nerve
terminals [2,48]. Both antivenoms tested in this work are effective
in the neutralisation of the lethal effect of Papuan O. scutellatus
venom after pre-incubation, thus evidencing their capacity to
neutralize the neurotoxins present in this venom.
Disruption of the integrity of skeletal muscle fibre plasma
membranes, with rapid impairment of the ability of this
membrane to regulate its permeability to ions and macromole-
cules, is induced by the myotoxic PLA2s, taipoxin and OS2, from
the venom of O. scutellatus [42,49–50]. Both of the tested
antivenoms effectively neutralised myotoxicity due to O. scutellatus
venom. Since the neurotoxic and myotoxic actions of taipoxin,
and similar presynaptically-acting neurotoxins, depend on PLA2
enzymatic activity of these toxins [51,52], the effectiveness of the
two antivenoms to neutralize PLA2 activity of O. scutellatus venom
is compatible with the neutralisation of these toxic activities.
Coagulopathy occurs in a majority of patients envenomed by O.
scutellatus in PNG [8]. This is due to the procoagulant effect of
serine proteinases that are potent prothrombin activators [53–55].
In agreement with previous studies [35–36], Papuan O. scutellatus
venom showed higher in vitro coagulant activity on plasma in
conditions where CaCl2 was added to plasma immediately before
venom. Regardless of whether the experiments were performed
with or without the addition of calcium, ICP antivenom showed a
higher potency for the neutralisation of coagulant effect.
Interestingly, ICP antivenom was also more effective in the
neutralisation of coagulant activity induced by venom from
Australian O. scutellatus. These observations suggest that the
differences shown by these antivenoms regarding neutralisation
of coagulant effect are not likely to be due to antigenic variations
in the procoagulant enzymes of these two populations of taipan,
but instead to a higher antibody titre against these enzymes of both
venoms in ICP antivenom. The basis of this finding remains to be
elucidated, but may have to do with differences in the
immunization schemes employed in the production of these
Table 2. Toxic activities of O. scutellatus venom and neutralisation by antivenoms.
Effect Activity ICP IgG antivenom (Batch 4511209 ICP) CSL F(ab’)2 antivenom (Batch B0548-06301)
mg Venom/mL Antivenomd Neutralising Unitse mg Venom/mL Antivenomd Neutralising Unitse
Lethality (i.p.) (LD50)
a 0.0460.01 mg 4.50 (3.18–6.41) 18,000 5.65 (3.89–8.77) 18,645
Lethality (i.v.) (LD50)
a 0.0860.01 mg 4.35 (3.05–5.29) 17,400 5.81 (4.08–7.04) 19,173
Coagulant (MCC)b
without calcium
0.7660.20 mg/mL 2.4360.29* 0.8460.04*
Coagulant (MCC) with
calcium
0.3360.13 mg/mL 2.3760.08* 0.4560.17*
Myotoxic (MMD)c 1 mg 4.0 4.0
PLA2 ( mEq/mg/min) 29767 1.4760.29 1.1060.38
aLethal activity was determined for the i.p. and i.v. routes in CD-1 mice. Median Lethal Dose (LD50) is expressed as mg venom/mouse (mean 6 S.D)
bCoagulant activity, expressed as the Minimum Coagulant Concentration (MCC), either in citrated plasma or in citrated plasma to which CaCl2 was added immediately
before the test. Results are the mean 6 S.D.
cMyotoxic activity, expressed as the Minimum Myotoxic Dose (MMD).
dNeutralisation is expressed as either ED50 (lethality and PLA2) or ED (coagulant and myotoxic effects) (see Materials and Method for details). Results are presented as mg
venom neutralised per mL antivenom. For lethality, the 95% confidence limits are included in parenthesis. For the other effects, results are presented as mean 6 S.D.
(n = 4–6). Challenge doses of venom correspond to 4 LD50s (lethality), 2 MCCs (coagulant), 1 MMD (myotoxicity), and 1.5 mg venom (PLA2 activity).
eCSL taipan antivenom is labelled as containing at least 12,000 Neutralising Units of antivenom, where 1 Unit = 0.01 mg venom neutralised (i.e.: 12,000 units neutralises
120 mg venom). Actual neutralising unit values for each antivenom are given here for comparison and are calculated from fill volumes of each product.
*p,0.05 when the two antivenoms are compared.
doi:10.1371/journal.pntd.0001144.t002
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antivenoms. It is recommended that the analysis of the
neutralisation of coagulant activity by Australian venoms by
antivenoms should be performed in conditions where calcium is
added to citrated plasma before the addition of venom, for reasons
previously described [35–36]. Clinical studies carried out in PNG
demonstrated that CSL taipan antivenom was effective at
restoring blood coagulability within 6–12 hr in 93% of patients
treated [8]. A future clinical trial will determine whether this
difference in the neutralisation of in vitro coagulant activity between
these antivenoms will translate into differences in their in vivo
clinical efficacy at restoring blood coagulability in envenomed
patients.
An unexpected observation during this study was the partial loss
of in vitro coagulant activity of the venom upon incubation at 37uC
for 30 min. Whether this observation is due to proteolytic
degradation or alteration in the quaternary structure of the
procoagulant present in this venom, or to a physiologically sub-
optimal environment in the in vitro coagulant activity assay remains
unknown. Notably, serine proteinase inhibitors had to be used in
the isolation of the prothrombin activator [54] and an apparent in
vivo inactivation of the coagulant activity of O. scutellatus venom was
described in a monkey model of envenoming [56]. Consequently,
we modified the coagulant activity neutralisation protocol in order
to avoid the incubation of venom at 37uC for 30 min. Although
this modification departs from the conventional way to assess
neutralization by antivenoms, i.e. incubation of venom-antivenom
mixtures for 30 min, a shorter incubation time, such as the one
adapted in this study, also allows a proper testing of neutralization
of this activity, since the binding of antibodies to antigens is a very
rapid phenomenon. Moreover, both antivenoms were able to
neutralize coagulant activity in these circumstances.
There were two important considerations in embarking upon a
project that is designed to develop an alternative to a currently
available product of established efficacy. These were:
N (a). Antivenom price.
From 1987 to 2007 the cost of CSL polyvalent and taipan
antivenoms to the Papua Guinea Department of Health increased
drastically, leading to a 40% decline in product availability
[57,58]. As a consequence, these antivenoms have become
increasingly unaffordable to a health system already under
enormous stress, leading to chronic antivenom shortages of
antivenom and negative patient outcomes [16]. The high prices
and relative scarcity have led to a flourishing black market, where
stolen antivenoms are resold by private pharmacies and unlicensed
wholesalers [17]. We have focused on the need to produce an
effective antivenom with a fill volume (40–50 mL) sufficient to
neutralize the average ‘‘milked’’ venom yield (120 mg) of healthy,
adult O. scutellatus, at the lowest sustainable price, as a means of
restoring access to affordable antivenom supplies.
N (b). Local capacity-building.
PNG currently lacks the capacity to produce its own antivenoms
or vaccines. Our successful collaborative development of a potent
experimental Papuan taipan antivenom demonstrates the rele-
vance of international partnership for approaching public health
issues. This project has allowed the development of PNG capacity
for venomous snake husbandry, and production of venoms for
immunization and quality control. Further efforts will be aimed at
strengthening other local capacities in PNG which, in the long
term, may lead to the sustainable manufacture of antivenoms in
this country.
In conclusion, a new low-cost whole IgG antivenom, obtained
by caprylic acid fractionation of horse plasma, was prepared
against the venom of O. scutellatus from PNG. The antivenom has a
satisfactory preclinical profile in the neutralisation of lethal, PLA2,
myotoxic and coagulant effects of O. scutellatus venom, comparable
to that of the F(ab’)2 antivenom currently in use in PNG. These
two antivenoms will be compared further in a randomised, non-
inferiority, controlled trial in PNG in order to determine the
clinical efficacy and safety profiles of both products.
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